Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -7% Improvement Relative Risk c19hcq.org Alghamdi et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 775 patients in Saudi Arabia No significant difference in mortality Alghamdi et al., Antibiotics, doi:10.3390/antibiotics10040365 Favors HCQ Favors control
Clinical Efficacy of Hydroxychloroquine in Patients with COVID-19: Findings from an Observational Comparative Study in Saudi Arabia
Alghamdi et al., Antibiotics, doi:10.3390/antibiotics10040365
Alghamdi et al., Clinical Efficacy of Hydroxychloroquine in Patients with COVID-19: Findings from an Observational Comparative.., Antibiotics, doi:10.3390/antibiotics10040365
Mar 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 775 hospitalized patients in Saudi Arabia showing no significant difference. There was no adjustment for severity or comorbidities. Confounding by indication is likely. This study is excluded in the after exclusion results of meta analysis: confounding by indication is likely and adjustments do not consider COVID-19 severity at baseline.
risk of death, 6.9% higher, RR 1.07, p = 0.88, treatment 44 of 568 (7.7%), control 15 of 207 (7.2%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Alghamdi et al., 31 Mar 2021, retrospective, Saudi Arabia, peer-reviewed, 10 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: antibiotics Article Clinical Efficacy of Hydroxychloroquine in Patients with COVID-19: Findings from an Observational Comparative Study in Saudi Arabia Saleh Alghamdi 1 , Bassant Barakat 1 , Ilhem Berrou 2, * , Abdulhakim Alzahrani 3 , Abdul Haseeb 4 , Mohamed Anwar Hammad 1 , Sirajudheen Anwar 5 , Abdulmajeed Abdulghani A. Sindi 6 , Hussain A. Almasmoum 7 and Mohammad Albanghali 8 1 2 3 4 5   6 7 Citation: Alghamdi, S.; Barakat, B.; Berrou, I.; Alzahrani, A.; Haseeb, A.; 8 Hammad, M.A.; Anwar, S.; Sindi, A.A.A.; Almasmoum, H.A.; * Department of Clinical Pharmacy, Faculty of Clinical Pharmacy, Albaha University, Albaha 57911, Saudi Arabia; saleh.alghamdi@bu.edu.sa (S.A.); bbarakat@bu.edu.sa (B.B.); m.anwar@bu.edu.sa (M.A.H.) School of Health and Social Wellbeing, University of the West of England, Staple Hill, Bristol BS16 1DD, UK Pharmaceutical Care Services Department, King Fahad Hospital, Albaha 57911, Saudi Arabia; aalzahrani116@moh.gov.sa Department of Clinical Pharmacy, College of Pharmacy, Umm Al-Qura University, Makkah 24231, Saudi Arabia; amhaseeb@uqu.edu.sa Department of Pharmacology and Toxicology, College of Pharmacy, University of Hail, Hail 55482, Saudi Arabia; si.anwar@uoh.edu.sa Department of Basic Medical Science, Faculty of Applied Medical Sciences, Albaha University, Albaha 57911, Saudi Arabia; asindi@bu.edu.sa Department of Laboratory Medicine, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah 24231, Saudi Arabia; Haamasmoum@uqu.edu.sa Department of Public Health, Faculty of Applied Medical Sciences, Albaha University, Albaha 57911, Saudi Arabia; mohammad.aref@bu.edu.sa Correspondence: ilhem.berrou@uwe.ac.uk; Tel.: +44-11732-84053 Albanghali, M. Clinical Efficacy of Hydroxychloroquine in Patients with COVID-19: Findings from an Observational Comparative Study in Saudi Arabia. Antibiotics 2021, 10, 365. https://doi.org/10.3390/ antibiotics10040365 Academic Editor: Nahed El-Najjar Received: 3 March 2021 Accepted: 28 March 2021 Published: 31 March 2021 Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. Abstract: The aim of this study was to assess the clinical effectiveness of Hydroxychloroquine-based regimens versus standard treatment in patients with the coronavirus disease admitted in 2019 to a hospital in Saudi Arabia. A comparative observational study, using routine hospital data, was carried out in a large tertiary care hospital in Al Baha, Saudi Arabia, providing care to patients with COVID-19 between April 2019 and August 2019. Patients were categorized into two groups: the Hydroxychloroquine (HCQ) group, treated with HCQ in a dose of 400 mg twice daily on the first day, followed by 200 mg twice daily; the non HCQ group, treated with other antiviral or antibacterial treatments according to protocols recommended by the Ministry of Health (MOH) at the time. The primary outcomes were the length of hospital stay, need for admission to the intensive care unit (ICU), time in ICU, and need for mechanical ventilation. Overall survival was also assessed. 568 patients who received HCQ (treatment group) were compared with 207 patients who did not receive HCQ (control group). HCQ did not improve mortality in the treated group (7.7% vs. 7.2%). There were no significant differences in terms of duration of hospitalization, need for and time in ICU, and need for mechanical ventilation among the groups. Our..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit